Eko Health Secures $41 Million to Revolutionize Heart and Lung Detection
June 6, 2024, 9:33 am
Location: United States, California, Oakland
Employees: 51-200
Founded date: 2013
Total raised: $20M
Location: United States, California, Oakland
Employees: 51-200
Founded date: 2013
Total raised: $162.7M
Eko Health, a trailblazer in the realm of AI-powered early detection of heart and lung diseases, has successfully closed a Series D financing round, raising an impressive $41 million. This significant funding round, spearheaded by ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, marks a pivotal moment in Eko's journey towards expanding access to its groundbreaking platform not only in the United States but also on a global scale.
Building upon a foundation of innovation and clinical validation, Eko has achieved remarkable milestones in both commercial and clinical arenas. Their AI algorithms designed for detecting structural heart murmurs and low ejection fraction (Low EF) have garnered FDA clearance in the United States. Noteworthy studies conducted at prestigious institutions such as Massachusetts General Hospital and Mayo Clinic have demonstrated the superior efficacy of Eko's algorithms in identifying structural heart murmurs and heart failure with reduced ejection fraction, respectively.
By enhancing detection capabilities through their platform, Eko is streamlining the diagnostic process, enabling earlier interventions, and ultimately improving patient outcomes. This is particularly crucial in light of the global burden posed by cardiovascular and pulmonary diseases, which remain leading causes of mortality worldwide. Millions of individuals go undiagnosed due to limited access to effective detection tools, and Eko is bridging this gap by seamlessly integrating advanced AI capabilities into routine physical exams across various healthcare settings, from primary care facilities in the United States to maternal-fetal health exams in Nigeria.
The infusion of capital from this latest funding round will enable Eko to solidify its presence in the United States while also accelerating its international expansion efforts in regions such as Europe, the Middle East, and Singapore. Strategic investments from Double Point Ventures, EDBI, and LG Technology Ventures further bolster Eko's growth trajectory, positioning the company to rapidly expand access to its AI-powered platform. This expansion will empower healthcare professionals worldwide to leverage cutting-edge technology in improving patient outcomes and revolutionizing disease detection practices.
In the words of Connor Landgraf, CEO and co-founder of Eko Health, "Eko harnesses AI to unlock universal access to expert-level cardiac and pulmonary disease detection for patients everywhere." Drawing parallels to the transformative impact of technologies like Ring in the realm of home security, Eko has reimagined the traditional stethoscope as a powerful early disease detection platform, boasting the world's largest install base of professional AI-enabled cardiology devices.
In conclusion, Eko Health's latest funding milestone not only underscores the company's commitment to innovation and clinical excellence but also heralds a new era in the field of healthcare technology. With a focus on expanding access to advanced disease detection tools and empowering healthcare professionals globally, Eko is poised to make a lasting impact on the landscape of cardiovascular and pulmonary care.
Building upon a foundation of innovation and clinical validation, Eko has achieved remarkable milestones in both commercial and clinical arenas. Their AI algorithms designed for detecting structural heart murmurs and low ejection fraction (Low EF) have garnered FDA clearance in the United States. Noteworthy studies conducted at prestigious institutions such as Massachusetts General Hospital and Mayo Clinic have demonstrated the superior efficacy of Eko's algorithms in identifying structural heart murmurs and heart failure with reduced ejection fraction, respectively.
By enhancing detection capabilities through their platform, Eko is streamlining the diagnostic process, enabling earlier interventions, and ultimately improving patient outcomes. This is particularly crucial in light of the global burden posed by cardiovascular and pulmonary diseases, which remain leading causes of mortality worldwide. Millions of individuals go undiagnosed due to limited access to effective detection tools, and Eko is bridging this gap by seamlessly integrating advanced AI capabilities into routine physical exams across various healthcare settings, from primary care facilities in the United States to maternal-fetal health exams in Nigeria.
The infusion of capital from this latest funding round will enable Eko to solidify its presence in the United States while also accelerating its international expansion efforts in regions such as Europe, the Middle East, and Singapore. Strategic investments from Double Point Ventures, EDBI, and LG Technology Ventures further bolster Eko's growth trajectory, positioning the company to rapidly expand access to its AI-powered platform. This expansion will empower healthcare professionals worldwide to leverage cutting-edge technology in improving patient outcomes and revolutionizing disease detection practices.
In the words of Connor Landgraf, CEO and co-founder of Eko Health, "Eko harnesses AI to unlock universal access to expert-level cardiac and pulmonary disease detection for patients everywhere." Drawing parallels to the transformative impact of technologies like Ring in the realm of home security, Eko has reimagined the traditional stethoscope as a powerful early disease detection platform, boasting the world's largest install base of professional AI-enabled cardiology devices.
In conclusion, Eko Health's latest funding milestone not only underscores the company's commitment to innovation and clinical excellence but also heralds a new era in the field of healthcare technology. With a focus on expanding access to advanced disease detection tools and empowering healthcare professionals globally, Eko is poised to make a lasting impact on the landscape of cardiovascular and pulmonary care.